Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.62Last Year’s EPS
0.7Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 23, 2025
|% Change Since: 6.33%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and strategic advancements, such as significant revenue growth and successful product approvals. However, challenges in the Japan market and anticipated financial impacts from tariffs and acquisitions present potential hurdles.Company Guidance
During the Edwards Lifesciences first-quarter 2025 earnings call, the company provided a comprehensive financial and strategic outlook for the year. Total company sales grew by 8% to $1.041 billion, driven by strong performance in the TAVR segment, which saw a 5.4% increase in global sales to $1.05 billion. The TMTT segment also demonstrated significant growth, with first-quarter sales of $150 million, representing a 60% increase. The company raised its 2025 TMTT sales guidance to $530 to $550 million, attributing the adjustment to favorable foreign exchange and business momentum. Edwards maintained its full-year total company sales growth guidance of 8% to 10% and EPS guidance of $2.40 to $2.50, despite anticipated impacts from tariffs and the upcoming Yenovale acquisition. The company expects second-quarter sales of $1.45 to $1.53 billion and adjusted earnings per share of $0.59 to $0.65. Looking ahead, Edwards is positioned to capitalize on new product approvals and market expansions, with initiatives like the anticipated early TAVR indication approval and the recent CE mark for the SAPIEN M3 mitral valve replacement system in Europe.8% Revenue Growth
Total company sales grew 8% to $1.041 billion in the first quarter of 2025, reflecting the benefits of a broad and differentiated portfolio.
TMTT Sales Increase
First-quarter sales of TMTT were $150 million, representing growth of about 60%, led by increased adoption and balanced contribution from Pascal and Evoque.
Raised 2025 TMTT Sales Guidance
The 2025 TMTT sales guidance range was raised to $530 to $550 million.
Milestone Achievements
Recent approval of SAPIEN M3 in Europe, NCD for Evoque, and strong performance in the Resilia Tissue technology.
Strong Financial Performance
Adjusted EPS of $0.64 in the quarter with solid operating performance, and a strong balance sheet with $3 billion in cash.
---
EW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 23, 2025 | $70.46 | $75.13 | +6.63% |
| Feb 11, 2025 | $70.91 | $75.82 | +6.92% |
| Oct 24, 2024 | $70.35 | $69.38 | -1.38% |
| Jul 24, 2024 | $86.95 | $59.70 | -31.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Edwards Lifesciences (EW) report earnings?
Edwards Lifesciences (EW) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Edwards Lifesciences (EW) earnings time?
Edwards Lifesciences (EW) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EW EPS forecast?
EW EPS forecast for the fiscal quarter 2025 (Q2) is 0.62.
---